Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Summary

This is a phase 1/2, open label, study designed to assess the safety and clinical activity of different Belantamab Mafodotin doses in combination with lenalidomide and dexamethasone.

Timeline

Start

2021-02-22

Primary completion

2028-09-08

Completion

2028-11-08

Publications

• Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M, Theodorakakou F, Spiliopoulou V, Solia E, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood. 2026 Apr 2;147(14):1574-1583. doi: 10.1182/blood.2025031629.
• Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kanellias N, Eleutherakis-Papaiakovou E, Roussou M, Psarros G, Kastritis E, Dimopoulos MA, Terpos E. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study. Am J Hematol. 2024 Mar;99(3):502-504. doi: 10.1002/ajh.27219. Epub 2024 Jan 25. No abstract available.

Drugs

Indications